Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646347 | 0.96 | USP2 (0.68) | ALDH1A1PKMPOLBHTTUSP2 | |
| SCHEMBL12189227 | 0.95 | USP2 (0.71) | ALDH1A1HTTUSP2HSD11B1THRB | |
| SCHEMBL12189230 | 0.86 | SMN1; SMN2 (0.78) | ALDH1A1POLBHTTUSP2THRB | |
| SCHEMBL1954250 | 0.85 | ALDH1A1 (0.56) | ALDH1A1PKMPOLBHTTUSP2 | |
| SCHEMBL12075773 | 0.84 | MAPT (0.63) | ALDH1A1PKMUSP2HSD11B1THRB | |
| SCHEMBL16111102 | 0.84 | KMT2A (0.63) | ALDH1A1USP2HSD11B1THRBL3MBTL1 | |
| SCHEMBL7904262 | 0.84 | ALDH1A1 (0.70) | ALDH1A1POLBUSP2L3MBTL1MEN1 | |
| SCHEMBL15010487 | 0.82 | USP2 (0.63) | ALDH1A1PKMPOLBHTTUSP2 | |
| SCHEMBL12189232 | 0.82 | ALDH1A1 (0.72) | ALDH1A1HTTUSP2HSD11B1THRB | |
| SCHEMBL22217089 | 0.81 | USP2 (0.62) | ALDH1A1PKMPOLBHTTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | ALDH1A1 780/4885PKM 590/4885POLB 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.